A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
Patients should discuss long-term goals and monitoring plans with prescribing clinicians to align treatment with individual risk profiles
Based on clinical trial data from Novo Nordisk, people who took the pill along with maintaining a reduced-calorie diet and increased physical activity lost an average of 13% of their body weight over 64 weeks
Press the You tab on mobile (bottom center)
If you have any questions during this time, you can reach the Prior Authorizations team directly by responding to the message titled PRIOR AUTH SUBMISSION or contact your pharmacy benefit plan directly
Once approved, you generally wont need another prior authorization for refills or dose changes through December 31, 2027